Showing 1891-1900 of 8649 results for "".
- American Academy of Ophthalmology In-Person Meeting Cancelledhttps://modernod.com/news/american-academy-of-ophthalmology-in-person-meeting-cancelled/2478008/Due to the COVID-19 pandemic, the American Academy of Ophthalmology (AAO) has cancelled its in-person annual meeting scheduled to take place in November in Las Vegas. “In light of epidemiological projections, government regulations and public health mandates to prevent the spread of
- FDA Priority Review Accepted for Eylea HD for Both the Treatment of RVO and for Monthly Dosing in Approved Indicationshttps://modernod.com/news/fda-priority-review-accepted-for-eylea-hd-for-both-the-treatment-of-rvo-and-for-monthly-dosing-in-approved-indications/2482741/Regeneron announced that the FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) Injection 8 mg. The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion (RVO
- Latinos En Optometry and VSP Vision Launch New Series Focused on Enhancing Cultural Competencyhttps://modernod.com/news/latinos-en-optometry-and-vsp-vision-launch-new-series-focused-on-enhancing-cultural-competency/2482689/Latinos en Optometry has collaborated with VSP Vision to launch a new blog series called “Cultural Responsiveness.” The initiative seeks to support both existing and prospective practitioners in understanding the importance of healthcare services that are responsive to the s
- GenSight Biologics Withdraws its EMA Application for Lumevoqhttps://modernod.com/news/gensight-biologics-withdraws-its-ema-application-for-lumevoq/2481559/GenSight Biologics announced that it has decided to withdraw an application with the European Medicines Agency (EMA) seeking approval of Lumevoq (lenadogene nolparvovec) in patients with Leber hereditary optic neuropathy (LHON). The moves comes after the Committee for Advanced Therapies (CAT
- Eyenovia Announces Development Collaboration with Formosa Pharmaceuticalshttps://modernod.com/news/eyenovia-announces-development-collaboration-with-formosa-pharmaceuticals/2481412/Eyenovia announced that the company has entered into a development collaboration agreement with Taiwan-based Formosa Pharmaceuticals that seeks to combine Eyenovia’s Optejet dispensing technology with Formosa’s APNT nanoparticle formulation platform for the potential develop
- Bausch + Lomb and Novaliq Submit New Drug Application for Investigational NOV03 for Dry Eye Disease Associated with MGDhttps://modernod.com/news/bausch-lomb-and-novaliq-submission-new-drug-application-for-investigational-nov03-for-dry-eye-disease-associated-with-mgd/2480972/Bausch + Lomb and Novaliq announced the submission of a new drug application (NDA) at the end of June to FDA seeking approval for NOV03 (perfluorohexyloctane), an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease (DED) associated
- New Paper Examines Top 10 Myths About Fitting Soft Contact Lenseshttps://modernod.com/news/new-paper-examines-top-10-myths-about-fitting-soft-contact-lenses/2480598/A new peer-review paper from the Centre for Ocular Research & Education (CORE) seeks to shift persistent views about contact lenses that are no longer accurate based on current evidence. Addressing common myths and mis
- Lilly Reaches Deal to Supply US With COVID-19 Antibody Treatment Bamlanivimabhttps://modernod.com/news/lilly-reaches-deal-to-supply-us-with-covid-19-antibody-treatment-bamlanivimab/2478472/Eli Lilly announced that it has signed a $375-million agreement with the US government to supply 300,000 vials of bamlanivimab, an investigational neutralizing antibody treatment for COVID-19. The company recently submitted a request to the FDA seeking emergency-use authorization (EUA) for bamlan
- Regeneron Asks FDA to Approve Emergency Use of REGN-COV2 for COVID-19https://modernod.com/news/regeneron-asks-fda-to-approve-emergency-use-of-regn-cov2-for-covid-19/2478394/Regeneron Pharmaceuticals said that it submitted a request to the FDA seeking emergency-use authorization for its REGN-COV2 investigational antibody combination for the treatment of COVID-19. REGN-COV2 is a combination of two monoclonal antibodies, REGN10933 and REGN10987, which has been designed
- GenSight Biologics Submits EU Marketing Authorization Application for LHON Gene Therapy Lumevoqhttps://modernod.com/news/gensight-biologics-submits-eu-marketing-authorization-application-for-lhon-gene-therapy-lumevoq/2478287/GenSight Biologics announced that it has submitted the Marketing Authorization Application (MAA) for its lead product Lumevoq to the European Medicines Agency (EMA), seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by mutation